Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T4030 vs Ganfort UD in glaucoma or ocular hypertension
2020-003979-18Phase 3Completed
- Sponsor
- Laboratoires Théa
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in open-angle glaucoma (OAG) and ocular hypertension comparing T4030 with Ganfort UD (2 arms). Primary endpoint: Change in intraocular pressure at Week 12 (08:00) in study eye. Started Dec 2020; status: completed.
02
Drugs
T4030bimatoprost + timolol
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2020-003979-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003979-18.